DiNAQOR Strengthens Leadership Team to Advance Biotechnology Company Building Strategy

DiNAQOR AG, an innovative health technology group advancing promising early-stage drug development, announced strategic leadership appointments that strengthen its position as a life science company builder focused on creating, scaling, and partnering next-generation biotechnology ventures. The appointments signal the company's commitment to translating breakthrough technologies into clinical and commercial success through enhanced strategic leadership and scientific expertise.

Dr. Christian Thirion has been appointed Chief Executive Officer and Delegate of the Board of Directors of DiNATEQ AG, the recently established DiNAQOR spin-out focused on clinical translation of the closed-loop loco-regional perfusion delivery platform. Additionally, Dr. Thirion assumes the newly created role of Chief Strategy and Business Development Officer of DiNAQOR AG, where he will lead group-wide corporate strategy, strategic partnerships, and M&A activities. Dr. Thirion brings more than two decades of entrepreneurial and executive leadership experience in the life sciences industry, having founded Sirion Biotech and led it as its long-standing Chief Executive Officer, building the company into a global market leader in viral vector engineering and AAV-based gene delivery. Under his leadership, Sirion Biotech became a preferred partner to leading pharmaceutical and biotechnology companies worldwide and was ultimately acquired by PerkinElmer in a landmark transaction.

Johannes Holzmeister, Founder of the DiNAQOR Group and Chairman and CEO of DINAQOR AG, stated that Dr. Thirion's appointment significantly strengthens the company's ability to build companies, execute partnerships, and translate breakthrough technologies into clinical and commercial success. Dr. Thirion added that DiNAQOR has built an exceptional ecosystem for turning scientific innovation into impactful biotechnology companies, noting that the closed-loop perfusion platform represents a truly differentiated delivery technology with potential to unlock multiple therapeutic modalities across organs. He expressed excitement about leading DiNATEQ at this pivotal stage and helping shape DiNAQOR's long-term strategy at the group level.

In parallel, DiNAQOR Group AG announced the appointment of Dr. Josef El Andari as Chief Scientific Officer of DiNAQOR AG. Dr. El Andari has been with DiNAQOR for more than four years and played a central role in advancing the company's scientific platforms, including development of the closed-loop perfusion technology from early concept through publication in leading peer-reviewed journals. His expertise spans genomic medicine, translational research, and advanced viral vector technologies, with particular focus on AAV design and bioengineering. Dr. El Andari commented that DiNAQOR has evolved into a uniquely integrated innovation engine for advanced therapies, and he is honored to continue working with teams and partners to translate rigorous science into therapies with real clinical impact.

These leadership changes occur as DiNAQOR AG operates as a life science company builder, creating and scaling focused biotechnology companies around differentiated technology platforms. The company has demonstrated its company-building and value-creation capabilities through successful strategic transactions, including the recent M&A of DiNAMIQS, a specialized adeno-associated virus manufacturing and development company. These developments underscore DiNAQOR's ability to identify high-impact technologies, build dedicated operating companies around them, and realize value through partnerships and strategic transactions with global industry leaders. The appointments of Dr. Thirion and Dr. El Andari represent strategic moves to accelerate the translation of the company's proprietary delivery platforms into therapies addressing significant unmet medical needs, while strengthening the group's position in the competitive biotechnology landscape.